Fig. 1
From: Recent advances in targeted therapies in acute myeloid leukemia
Approach to frontline treatment of AML with FDA-approved therapies in 2022. Treatment algorithm of AML induction and maintenance therapy is shown. AML Acute myeloid leukemia, GO Gemtuzumab ozogamicin, MIDO Midostaurin, HMA Hypomethylating agent, VEN Venetoclax, ENA Enasidenib; IVO Ivosidenib, LDAC Low-dose cytarabine, alloHSCT Allogeneic stem cell transplantation, MRD Measurable residual disease, CR Complete remission